Skip to main content

Table 1 Case series of infants treated with paracetamol for patent ductus arteriosus (PDA)

From: Efficacy and safety of intravenous paracetamol in comparison to ibuprofen for the treatment of patent ductus arteriosus in preterm infants: study protocol for a randomized control trial

Author Year Number of patients GA (weeks) BW (g) Postnatal age (days) Daily dosage/administration route No. of PDA closure Safety issues
Hammerman 2012 [13] 5 26–32 720–1210 3–35 60 mg/kg oral 5/5 No toxicity observed.
Oncel 2013 [14] 8 27–34 630–2970 5–27 60 mg/kg oral 7/8 Pre-treatment and post-treatment liver enzymes were normal in all patients.
Oncel 2013 [15] 10 24–30 590–990 2–15 60 mg/kg intravenous 10/10 No adverse effects were observed. Pre-treatment and post-treatment liver enzymes were normal in all patients.
Yurttutan 2013 [16] 6 26–33 920–1600 3–7 60 mg/kg oral 5/6 No adverse side effects were observed. Pre-treatment and post-treatment liver enzymes and bilirubin were normal in all patients.
Ozdemir 2013 [17] 7 23–32 620–1615 20–47 60 mg/kg oral 5/7 No side effects, no hepatotoxicity, and no abnormalities in the hematologic and biochemical analyses.
Sinha 2013 [18] 10 27–33 800–1380 4–7 45 mg/kg oral 10/10 No side effects related to paracetamol.
Jasani 2013 [19] 6 28–31 1040–1235 2–8 60 mg/kg oral 6/6 No adverse effects. Pre-treatment and post-treatment liver enzymes were normal in all neonates.
Kessel 2014 [20] 7 26–30 789–1322 not available 60 mg/kg oral 7/7 No side effects related to paracetamol.
Terrin 2014 [21] 8 24–28 551–897 38–94 h 60 mg/kg intravenous 6/8 No side effects related to paracetamol.
Nadir 2014 [22] 7 24–27 656–951 2–22 60 mg/kg oral 5/7 No abnormalities in hematologic and biochemical analyses.